Literature DB >> 2944575

Differential effects of recombinant human leukocyte interferons on cell surface antigen expression.

J W Greiner, P B Fisher, S Pestka, J Schlom.   

Abstract

Human leukocyte (alpha) interferon (IFN-alpha) is composed of a multigene family within which at least eight different species have been expressed in Escherichia coli, isolated, and shown to exert a wide range of biological activities on different human target cells. In this study we utilized eight species of IFN-alpha (A, B, C, D, F, I, J, and K) and investigated their respective capabilities to alter the proliferation of a human breast carcinoma cell line (MCF-7). The antigens studied were all constitutively expressed on the MCF-7 cell surface: the Mr 180,000 carcinoembryonic antigen; a high molecular weight (greater than 10(6] glycoprotein, termed tumor-associated glycoprotein 72; and a major HLA histocompatibility antigen. The level of expression of each antigen was measured by the binding of monoclonal antibodies B1.1, B72.3, and W6/32, respectively. A high degree of diversity was found among the various IFN-alpha species with respect to their ability to enhance antigen expression and inhibit MCF-7 cell growth. The two most potent species, IFN-alpha A and IFN-alpha B, were found to increase the expression of tumor antigens as well as the HLA determinant by 2-5-fold. In contrast, IFN-alpha D and IFN-alpha J were virtually inactive in altering antigen expression but did inhibit the growth of MCF-7 cells. The remaining IFN-alpha species, -alpha C, -alpha F, -alpha I, and -alpha K, exerted an intermediate range of activities for both antigen enhancement and inhibition of MCF-7 cell growth. The relative ability of each species of IFN-alpha to inhibit MCF-7 cell growth appeared to be independent of their effectiveness in augmenting antigen expression. IFN-alpha D and IFN-alpha J, the two species that failed to alter tumor antigen expression, did, however, seem to interact with the interferon receptor since they inhibited MCF-7 cell growth and competed with other IFN-alpha species for the increase in carcinoembryonic antigen, tumor-associated glycoprotein 72, or HLA expression. A comparison of the concentrations of each IFN-alpha necessary to enhance antigen expression revealed that the surface HLA determinant was approximately 10-fold more sensitive to enhancement than was the tumor antigen, carcinoembryonic antigen. The individual members of the IFN-alpha family thus differ extensively in their ability to alter the level of antigen expression on the surface of MCF-7 breast carcinoma cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944575

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Authors:  Megan C Duggan; Caroline Jochems; Renee N Donahue; Jacob Richards; Volodymyr Karpa; Elizabeth Foust; Bonnie Paul; Taylor Brooks; Susheela Tridandapani; Thomas Olencki; Xueliang Pan; Gregory B Lesinski; Jeffrey Schlom; William E Carson Iii
Journal:  Cancer Immunol Immunother       Date:  2016-08-31       Impact factor: 6.968

2.  Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons.

Authors:  J A Leon; M C Gutierrez; H Jiang; A Estabrook; S Waxman; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Effects of interferon gamma on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines.

Authors:  V J Möbus; W Asphal; P G Knapstein; R Kreienberg
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.

Authors:  Carolina Scagnolari; Milvia Casato; Francesca Bellomi; Francesca De Pisa; Ombretta Turriziani; Rossella Coviello; Maria Rosaria Pirro; Ferdinando Dianzani; Guido Antonelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

5.  Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon.

Authors:  F Guadagni; J Schlom; S Pothen; S Pestka; J W Greiner
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 6.  Dermatomyositis after interferon alpha treatment.

Authors:  L L Dietrich; A J Bridges; M R Albertini
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.738

7.  Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.

Authors:  G Scambia; P Benedetti Panici; L Perrone; C Sonsini; S Giannelli; A Gallo; P G Natali; S Mancuso
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

8.  Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.

Authors:  C Natoli; C Garufi; N Tinari; M D'Egidio; G Lesti; L A Gaspari; R Visini; S Iacobelli
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

9.  Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile.

Authors:  A M Yee; J P Buyon; Y K Yip
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.